Cimavax EGF, a therapeutic lung cancer vaccine was unvciled last week during a press conference in Cuba. Cuban scientists say that Cimavax EGF is the first in the world and extends the lives of victims suffering lung cancer by up to five months.
Cimavax EGF is the first registered vaccine in the world designed to battle lung cancer, said Gisela Gonzales of the Havana Molecular Immunological Center. Research on this vaccine, Gonzalez said, began in 1992, with the first clinical test in 1995.
The vaccine is based on two proteins that triggers an immune response from the victims body and has no side effect, Gonzalez said. The vaccine is available in Cuba, and will be commercialized in Latin America, starting in Peru, Gonzalez added.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment